Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma
1997

HLA Phenotypes and Response to Interleukin 2 in Kidney Cancer

Sample size: 79 publication Evidence: moderate

Author Information

Author(s): C Bain, Y Merrouche, I Puisieux, J-Y Blay, S Negrier, V Bonadona, C Lasset, F Lanier, A Duc, L Gebuhrer, T Philip, M C Favrot

Primary Institution: Centre Leon Berard

Hypothesis

Is there a correlation between HLA phenotypes and clinical response to interleukin 2 in patients with metastatic renal cell carcinoma?

Conclusion

The study found that certain HLA phenotypes, particularly A32, are associated with a better clinical response to interleukin 2 treatment in metastatic renal cell carcinoma patients.

Supporting Evidence

  • HLA-A32 was associated with a clinical response (p=0.025).
  • The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (p=0.008).
  • 61% of responder patients expressed HLA-A3 and/or A32 compared to 28% of non-responders.

Takeaway

This study looked at how certain genes in our body might help some kidney cancer patients respond better to a treatment called interleukin 2.

Methodology

HLA phenotyping was performed on peripheral blood mononuclear cells from patients treated with interleukin 2, and the results were compared to a control group.

Limitations

The study had a small sample size, which limits the ability to draw definitive conclusions.

Participant Demographics

Patients were of European ancestry, with a median age of 55 years.

Statistical Information

P-Value

0.025

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication